Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Pulse Biosciences, Inc. | plse-20160907xex99_1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
___________________________________________
FORM 8-K
___________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
September 7, 2016
___________________________________________
Pulse Biosciences, Inc.
(Exact name of registrant as specified in its charter)
___________________________________________
|
Nevada |
001-37744 |
46-5696597 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
849 Mitten Road
Burlingame, California 94010
(Address of principal executive offices, including zip code)
(650) 697-3939
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
___________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
|
|
☐ |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐ |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐ |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐ |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On September 7, 2016, Pulse Biosciences, Inc. (the “Company”) announced an update on its corporate progress, strategic focus and future milestones, including its financial results for the quarter ended June 30, 2016. In the press release, the Company also announced that it would be holding a conference call on September 7, 2016 to discuss the update and results. A copy of the press release containing the announcement is included as Exhibit 99.1 and is incorporated herein by reference.
This information, as well as Exhibit 99.1, is intended to be furnished under Item 2.02 of Form 8-K, “Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
|
ITEM 9.01. |
FINANCIAL STATEMENTS AND EXHIBITS. |
||||
|
|
|
||||
|
(d) |
|
Exhibits. |
|||
|
|
|
|
|||
|
99.1 |
|
Press Release issued by Pulse Biosciences, Inc. dated September 7, 2016. |
|||
|
|
|
|
|||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Pulse Biosciences, Inc. |
|
|
|
|
|
|
|
|
|
By: |
/s/ Brian B. Dow |
|
|
|
|
Brian B. Dow |
|
|
|
|
Senior Vice President and Chief Financial Officer |
|
Date: September 7, 2016
EXHIBIT INDEX
|
|
|
|
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release issued by Pulse Biosciences, Inc. dated September 7, 2016. |